Scientists probe hidden Hormone's role in prediabetes
NCT ID NCT06967558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a hormone called GLP-1, made in the pancreas, helps control blood sugar in people with prediabetes. Researchers will give a drug that blocks GLP-1 to see how it changes insulin and glucagon release. The goal is to understand why some people with prediabetes go on to develop type 2 diabetes. About 60 adults with stable weight and no diabetes will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Exendin 9-39 (a GLP-1 receptor blocker)
- What this could lead to
- If successful, this could reveal why some people with prediabetes develop type 2 diabetes, pointing toward new prevention strategies.
- What could go wrong
- This is a small, early-phase study focused on understanding biology, not testing a treatment. Results may not lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new rice could tame blood sugar spikes in prediabetes
- Could everyday supplements turn back the clock on aging?
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?
- Could a daily glass of milk help ward off type 2 diabetes?
- Can one avocado a day sharpen the aging brain?